ADTRALZA 300 mg, solution for injection in a pre-filled pen 2 syringes of 2 ml
Active ingredients: Tralokinumab
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injection2 syringes of 2 mlsous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- ADTRALZA 300 mg, solution injectable en stylo prérempli
- Pharmaceutical form
- solution injectable
- Route of administration
- sous-cutanée
- Presentation description
- 2 seringues préremplies en verre siliconé de 2 mL dans stylos pré-remplis
- Marketing authorisation holder
- LEO PHARMACEUTICAL PRODUCTS (DANEMARK)
- Reimbursement according to BDPM
- 65 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 25 Mar 2024
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
64854878CIP73027613CIP133400930276136Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| TRALOKINUMABsolution | 300 mg · un stylo prérempli de 2 mL | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.